Healthy Male Subjects

11
Pipeline Programs
8
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
11
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Celltrion
CelltrionKorea - Incheon
4 programs
4
CT-P41Phase 11 trial
CT-P43Phase 11 trial
CT-P52Phase 11 trial
CT-P55Phase 11 trial
Active Trials
NCT04512872Completed30Est. May 2021
NCT06951828Completed162Est. Dec 2025
NCT07367958Not Yet Recruiting218Est. Jan 2027
+1 more trials
RAPT Therapeutics
RAPT TherapeuticsSOUTH SAN FRANCISCO, CA
1 program
1
14C RPT193Phase 11 trial
Active Trials
NCT06087978CompletedEst. Oct 2023
Alvotech
AlvotechLUXEMBOURG, Luxembourg
1 program
1
AVT03Phase 11 trial
Active Trials
NCT05126784Completed209Est. Oct 2023
Enzene Biosciences
Enzene BiosciencesIndia - Pune
1 program
1
ENZ215Phase 11 trial
Active Trials
NCT05245669Completed207Est. May 2024
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
Fixed-Dose Combination of Pertuzumab and Trastuzumab SCPhase 11 trial
Active Trials
NCT05275010Completed151Est. Oct 2023
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
1 program
1
KW-6356Phase 11 trial
Active Trials
NCT04147910Completed8Est. Oct 2019
Biogen
BiogenCAMBRIDGE, MA
1 program
1
[14C]-OmaveloxolonePhase 11 trial
Active Trials
NCT03931590Completed8Est. May 2019
Vigonvita
VigonvitaChina - Suzhou
1 program
1
[14C]TPN171HPhase 11 trial
Active Trials
NCT04655872CompletedEst. Jan 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
CelltrionCT-P52
CelltrionCT-P43
CelltrionCT-P55
RAPT Therapeutics14C RPT193
AlvotechAVT03
RocheFixed-Dose Combination of Pertuzumab and Trastuzumab SC
Enzene BiosciencesENZ215
Vigonvita[14C]TPN171H
CelltrionCT-P41
Kyowa Hakko KirinKW-6356
Biogen[14C]-Omaveloxolone

Clinical Trials (11)

Total enrollment: 1,165 patients across 11 trials

A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects

Start: Jan 2026Est. completion: Jan 2027218 patients
Phase 1Not Yet Recruiting

A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects

Start: May 2025Est. completion: Dec 2025162 patients
Phase 1Completed

To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects

Start: Jan 2024Est. completion: Sep 2024172 patients
Phase 1Completed

Study of RPT193 in Healthy Adult Male Subjects

Start: Jul 2023Est. completion: Oct 2023
Phase 1Completed

AVT03 With Prolia in Healthy Male Subjects

Start: Jun 2022Est. completion: Oct 2023209 patients
Phase 1Completed
NCT05275010RocheFixed-Dose Combination of Pertuzumab and Trastuzumab SC

A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System

Start: May 2022Est. completion: Oct 2023151 patients
Phase 1Completed

Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers

Start: Jan 2022Est. completion: May 2024207 patients
Phase 1Completed

Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects

Start: Nov 2020Est. completion: Jan 2021
Phase 1Completed

A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects

Start: Oct 2020Est. completion: May 202130 patients
Phase 1Completed

Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356

Start: Aug 2019Est. completion: Oct 20198 patients
Phase 1Completed
NCT03931590Biogen[14C]-Omaveloxolone

A Human AME Study for Omaveloxolone

Start: Apr 2019Est. completion: May 20198 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

8 companies competing in this space